Epoxyeicosatrienoic acid analog EET-A blunts development of lupus nephritis in mice

Md Abdul Hye Khan, Anna Stavniichuk, Mohammad Abdul Sattar, J R Falck, John D. Imig

Research output: Contribution to journalArticle

Abstract

Systemic lupus erythematosus (SLE) is a chronic autoimmune inflammatory disorder that causes life threatening renal disease and current therapies are limited with serious side-effects. CYP epoxygenase metabolites of arachidonic acid epoxyeicosatrienoic acids (EETs) demonstrate strong anti-inflammatory and kidney protective actions. We investigated the ability of an orally active EET analog, EET-A to prevent kidney injury in a mouse SLE model. Twenty-weeks old female NZBWF1 (SLE) and age-matched NZW/LacJ (Non SLE) were treated with vehicle or EET-A (10 mg/kg/d, p.o.) for 14 weeks and urine and kidney tissues were collected at the end of the protocol. SLE mice demonstrated marked renal chemotaxis with 30-60% higher renal mRNA expression of CXC chemokine receptors (CXCR) and CXC chemokines (CXCL) compared to Non SLE mice. In SLE mice, the elevated chemotaxis is associated with 5-15-fold increase in cytokine mRNA expression and elevated inflammatory cell infiltration in the kidney. SLE mice also had elevated BUN, serum creatinine, proteinuria, and renal fibrosis. Interestingly, EET-A treatment markedly diminished renal CXCR and CXCL renal mRNA expression in SLE mice. EET-A treatment also reduced renal TNF-a, IL-6, IL-1β, and IFN-γ mRNA expression by 70-80% in SLE mice. Along with reductions in renal chemokine and cytokine mRNA expression, EET-A reduced renal immune cell infiltration, BUN, serum creatinine, proteinuria and renal fibrosis in SLE mice. Overall, we demonstrate that an orally active EET analog, EET-A prevents renal injury in a mouse model of SLE by reducing inflammation.

Original languageEnglish (US)
Article number512
JournalFrontiers in Pharmacology
Volume10
Issue numberMAY
DOIs
StatePublished - Jan 1 2019

Fingerprint

Lupus Nephritis
Systemic Lupus Erythematosus
Kidney
Acids
CXCR Receptors
Messenger RNA
Blood Urea Nitrogen
Chemotaxis
Proteinuria
Creatinine
Fibrosis
Cytokines
CXC Chemokines
Aptitude
Wounds and Injuries
Serum
Interleukin-1
Chemokines

Keywords

  • Chemokine
  • EET analog
  • Inflammation
  • Lupus nephritis
  • Mouse
  • Small lipid mediators

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Epoxyeicosatrienoic acid analog EET-A blunts development of lupus nephritis in mice. / Khan, Md Abdul Hye; Stavniichuk, Anna; Sattar, Mohammad Abdul; Falck, J R; Imig, John D.

In: Frontiers in Pharmacology, Vol. 10, No. MAY, 512, 01.01.2019.

Research output: Contribution to journalArticle

Khan, Md Abdul Hye ; Stavniichuk, Anna ; Sattar, Mohammad Abdul ; Falck, J R ; Imig, John D. / Epoxyeicosatrienoic acid analog EET-A blunts development of lupus nephritis in mice. In: Frontiers in Pharmacology. 2019 ; Vol. 10, No. MAY.
@article{7c9d7438432e48edac66fa90f667a38e,
title = "Epoxyeicosatrienoic acid analog EET-A blunts development of lupus nephritis in mice",
abstract = "Systemic lupus erythematosus (SLE) is a chronic autoimmune inflammatory disorder that causes life threatening renal disease and current therapies are limited with serious side-effects. CYP epoxygenase metabolites of arachidonic acid epoxyeicosatrienoic acids (EETs) demonstrate strong anti-inflammatory and kidney protective actions. We investigated the ability of an orally active EET analog, EET-A to prevent kidney injury in a mouse SLE model. Twenty-weeks old female NZBWF1 (SLE) and age-matched NZW/LacJ (Non SLE) were treated with vehicle or EET-A (10 mg/kg/d, p.o.) for 14 weeks and urine and kidney tissues were collected at the end of the protocol. SLE mice demonstrated marked renal chemotaxis with 30-60{\%} higher renal mRNA expression of CXC chemokine receptors (CXCR) and CXC chemokines (CXCL) compared to Non SLE mice. In SLE mice, the elevated chemotaxis is associated with 5-15-fold increase in cytokine mRNA expression and elevated inflammatory cell infiltration in the kidney. SLE mice also had elevated BUN, serum creatinine, proteinuria, and renal fibrosis. Interestingly, EET-A treatment markedly diminished renal CXCR and CXCL renal mRNA expression in SLE mice. EET-A treatment also reduced renal TNF-a, IL-6, IL-1β, and IFN-γ mRNA expression by 70-80{\%} in SLE mice. Along with reductions in renal chemokine and cytokine mRNA expression, EET-A reduced renal immune cell infiltration, BUN, serum creatinine, proteinuria and renal fibrosis in SLE mice. Overall, we demonstrate that an orally active EET analog, EET-A prevents renal injury in a mouse model of SLE by reducing inflammation.",
keywords = "Chemokine, EET analog, Inflammation, Lupus nephritis, Mouse, Small lipid mediators",
author = "Khan, {Md Abdul Hye} and Anna Stavniichuk and Sattar, {Mohammad Abdul} and Falck, {J R} and Imig, {John D.}",
year = "2019",
month = "1",
day = "1",
doi = "10.3389/fphar.2019.00512",
language = "English (US)",
volume = "10",
journal = "Frontiers in Pharmacology",
issn = "1663-9812",
publisher = "Frontiers Media S. A.",
number = "MAY",

}

TY - JOUR

T1 - Epoxyeicosatrienoic acid analog EET-A blunts development of lupus nephritis in mice

AU - Khan, Md Abdul Hye

AU - Stavniichuk, Anna

AU - Sattar, Mohammad Abdul

AU - Falck, J R

AU - Imig, John D.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Systemic lupus erythematosus (SLE) is a chronic autoimmune inflammatory disorder that causes life threatening renal disease and current therapies are limited with serious side-effects. CYP epoxygenase metabolites of arachidonic acid epoxyeicosatrienoic acids (EETs) demonstrate strong anti-inflammatory and kidney protective actions. We investigated the ability of an orally active EET analog, EET-A to prevent kidney injury in a mouse SLE model. Twenty-weeks old female NZBWF1 (SLE) and age-matched NZW/LacJ (Non SLE) were treated with vehicle or EET-A (10 mg/kg/d, p.o.) for 14 weeks and urine and kidney tissues were collected at the end of the protocol. SLE mice demonstrated marked renal chemotaxis with 30-60% higher renal mRNA expression of CXC chemokine receptors (CXCR) and CXC chemokines (CXCL) compared to Non SLE mice. In SLE mice, the elevated chemotaxis is associated with 5-15-fold increase in cytokine mRNA expression and elevated inflammatory cell infiltration in the kidney. SLE mice also had elevated BUN, serum creatinine, proteinuria, and renal fibrosis. Interestingly, EET-A treatment markedly diminished renal CXCR and CXCL renal mRNA expression in SLE mice. EET-A treatment also reduced renal TNF-a, IL-6, IL-1β, and IFN-γ mRNA expression by 70-80% in SLE mice. Along with reductions in renal chemokine and cytokine mRNA expression, EET-A reduced renal immune cell infiltration, BUN, serum creatinine, proteinuria and renal fibrosis in SLE mice. Overall, we demonstrate that an orally active EET analog, EET-A prevents renal injury in a mouse model of SLE by reducing inflammation.

AB - Systemic lupus erythematosus (SLE) is a chronic autoimmune inflammatory disorder that causes life threatening renal disease and current therapies are limited with serious side-effects. CYP epoxygenase metabolites of arachidonic acid epoxyeicosatrienoic acids (EETs) demonstrate strong anti-inflammatory and kidney protective actions. We investigated the ability of an orally active EET analog, EET-A to prevent kidney injury in a mouse SLE model. Twenty-weeks old female NZBWF1 (SLE) and age-matched NZW/LacJ (Non SLE) were treated with vehicle or EET-A (10 mg/kg/d, p.o.) for 14 weeks and urine and kidney tissues were collected at the end of the protocol. SLE mice demonstrated marked renal chemotaxis with 30-60% higher renal mRNA expression of CXC chemokine receptors (CXCR) and CXC chemokines (CXCL) compared to Non SLE mice. In SLE mice, the elevated chemotaxis is associated with 5-15-fold increase in cytokine mRNA expression and elevated inflammatory cell infiltration in the kidney. SLE mice also had elevated BUN, serum creatinine, proteinuria, and renal fibrosis. Interestingly, EET-A treatment markedly diminished renal CXCR and CXCL renal mRNA expression in SLE mice. EET-A treatment also reduced renal TNF-a, IL-6, IL-1β, and IFN-γ mRNA expression by 70-80% in SLE mice. Along with reductions in renal chemokine and cytokine mRNA expression, EET-A reduced renal immune cell infiltration, BUN, serum creatinine, proteinuria and renal fibrosis in SLE mice. Overall, we demonstrate that an orally active EET analog, EET-A prevents renal injury in a mouse model of SLE by reducing inflammation.

KW - Chemokine

KW - EET analog

KW - Inflammation

KW - Lupus nephritis

KW - Mouse

KW - Small lipid mediators

UR - http://www.scopus.com/inward/record.url?scp=85068851851&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068851851&partnerID=8YFLogxK

U2 - 10.3389/fphar.2019.00512

DO - 10.3389/fphar.2019.00512

M3 - Article

VL - 10

JO - Frontiers in Pharmacology

JF - Frontiers in Pharmacology

SN - 1663-9812

IS - MAY

M1 - 512

ER -